|
1
|
Zhang B, Li L, Ho Y, Li M, Marcucci G,
Tong W and Bhatia R: Heterogeneity of leukemia-initiating capacity
of chronic myelogenous leukemia stem cells. J Clin Invest.
126:975–991. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
2
|
Valera ET, Scrideli CA, Queiroz RG, Mori
BM and Tone LG: Multiple drug resistance protein (MDR-1), multidrug
resistance-related protein (MRP) and lung resistance protein (LRP)
gene expression in childhood acute lymphoblastic leukemia. Sao
Paulo Med J. 122:166–171. 2004.PubMed/NCBI View Article : Google Scholar
|
|
3
|
O'Hare T, Corbin AS and Druker BJ:
Targeted cml therapy: Controlling drug resistance, seeking cure.
Curr Opin Genet Dev. 16:92–99. 2006.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Gora-Tybor J: Emerging therapies in
chronic myeloid leukemia. Curr Cancer Drug Targets. 12:458–470.
2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Baccarani M, Deininger MW, Rosti G,
Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes
JE, Guilhot F, et al: European LeukemiaNet recommendations for the
management of chronic myeloid leukemia: 2013. Blood. 122:872–884.
2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Luqmani YA: Mechanisms of drug resistance
in cancer chemotherapy. Med Prin Pract. 14 (Suppl 1):S35–S48.
2005.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wang X, Chen B, Zhao L, Zhi D, Hai Y, Song
P, Li Y, Xie Q, Inam U, Wu Z, et al: Autophagy enhanced antitumor
effect in k562 and k562/ADM cells using realgar transforming
solution. Biomed Pharmacother. 98:252–264. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Dyshlovoy SA, Pelageev DN, Hauschild J,
Borisova KL, Kaune M, Krisp C, Venz S, Sabutskii YE, Khmelevskaya
EA, Busenbender T, et al: Successful targeting of the warburg
effect in prostate cancer by glucose-conjugated
1,4-Naphthoquinones. Cancers (Basel). 11(1690)2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Koppenol WH, Bounds PL and Dang CV: Otto
Warburg's contributions to current concepts of cancer metabolism.
Nat Rev Cancer. 11:325–337. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
10
|
Liberti MV and Locasale JW: The warburg
effect: How does it benefit cancer cells? Trends Biochem Sci.
41:211–218. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bhattacharya B, Mohd Omar MF and Soong R:
The warburg effect and drug resistance. Br J Pharmacol.
173:970–979. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Li L, Liang Y, Kang L, Liu Y, Gao S, Chen
S, Li Y, You W, Dong Q, Hong T, et al: Transcriptional regulation
of the warburg effect in cancer by six1. Cancer Cell.
33:368–385.e7. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ni Z, He J, Wu Y, Hu C, Dai X, Yan X, Li
B, Li X, Xiong H, Li Y, et al: Akt-mediated phosphorylation of
ATG4B impairs mitochondrial activity and enhances the warburg
effect in hepatocellular carcinoma cells. Autophagy. 14:685–701.
2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Fu D, Li J, Wei J, Zhang Z, Luo Y, Tan H
and Ren C: HMGB2 is associated with malignancy and regulates
Warburg effect by targeting LDHB and FBP1 in breast cancer. Cell
Commun Signal. 16(8)2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
de Andrade Barreto E, de Souza Santos PT,
Bergmann A, de Oliveira IM, Wernersbach Pinto L, Blanco T, Rossini
A, Pinto Kruel CD, Mattos Albano R and Ribeiro Pinto LF:
Alterations in glucose metabolism proteins responsible for the
warburg effect in esophageal squamous cell carcinoma. Exp Mol
Pathol. 101:66–73. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 44:646–674. 2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Barnes K, Mcintosh E, Whetton AD, Daley
GQ, Bentley J and Baldwin SA: Chronic myeloid leukaemia: An
investigation into the role of Bcr-Abl-induced abnormalities in
glucose transport regulation. Oncogene. 24:3257–3267.
2005.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Wang YH and Scadden DT: Targeting the
warburg effect for leukemia therapy: Magnitude matters. Mol Cell
Oncol. 2(e981988)2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Brittain EL: Clinical trials targeting
metabolism in pulmonary arterial hypertension. Adv Pulm Hypertens.
17:110–114. 2018.
|
|
20
|
Yeung SJ, Pan J and Lee MH: Roles of p53,
MYC and HIF-1 in regulating glycolysis-the seventh hallmark of
cancer. Cell Mol Life Sci. 65:3981–3999. 2008.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Szakács G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Zhu W, Huang Y, Pan Q, Xiang P, Xie N and
Yu H: MicroRNA-98 suppress warburg effect by targeting HK2 in colon
cancer cells. Dig Dis Sci. 62:660–668. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhang S, Pei M, Li Z, Li H, Liu Y and Li
J: Double-negative feedback interaction between DNA
methyltransferase 3A and microRNA-145 in the warburg effect of
ovarian cancer cells. Cancer Sci. 109:2734–2745. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Fathullahzadeh S, Mirzaei H, Honardoost
MA, Sahebkar A and Salehi M: Circulating microRNA-192 as a
diagnostic biomarker in human chronic lymphocytic leukemia. Cancer
Gene Ther. 23:327–332. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ichihara A, Wang Z, Jinnin M, Izuno Y,
Shimozono N, Yamane K, Fujisawa A, Moriya C, Fukushima S, Inoue Y
and Ihn H: Upregulation of miR-18a-5p contributes to epidermal
necrolysis in severe drug eruptions. J Allergy Clin Immunol.
133:1065–1074. 2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Xu XL, Jiang YH, Feng JG, Su D, Chen PC
and Mao WM: MicroRNA-17, microRNA-18a, and microRNA-19a are
prognostic indicators in esophageal squamous cell carcinoma. Ann
Thorac Surg. 97:1037–1045. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Takakura S, Mitsutake N, Nakashima M,
Namba H, Saenko VA, Rogounovitch TI, Nakazawa Y, Hayashi T, Ohtsuru
A and Yamashita S: Oncogenic role of miR-17-92 cluster in
anaplastic thyroid cancer cells. Cancer Sci. 99:1147–1154.
2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Liang C, Zhang X, Wang HM, Liu XM, Zhang
XJ, Zheng B, Qian GR and Ma ZL: MicroRNA-18a-5p functions as an
oncogene by directly targeting IRF2 in lung cancer. Cell Death Dis.
8(e2764)2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhang G, Han G, Zhang X, Yu Q, Li Z, Li Z
and Li J: Long non-coding RNA FENDRR reduces prostate cancer
malignancy by competitively binding miR-18a-5p with RUNX1.
Biomarkers. 23:435–445. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Li B, He L, Zuo D, He W, Wang Y, Zhang Y,
Liu W and Yuan Y: Mutual Regulation of MiR-199a-5p and HIF-1α
modulates the warburg effect in hepatocellular carcinoma. J Cancer.
8:940–949. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Icard P, Shulman S, Farhat D, Steyaert JM,
Alifano M and Lincet H: How the Warburg effect supports
aggressiveness and drug resistance of cancer cells? Drug Resist
Updates. 38:1–11. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Lévy P and Bartosch B: Metabolic
reprogramming: A hallmark of viral oncogenesis. Oncogene.
35:4155–4164. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Semenza GL: HIF-1 mediates the warburg
effect in clear cell renal carcinoma. J Bioenerg Biomembr.
39:231–234. 2007.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Rothschild SI: microRNA therapies in
cancer. Mol Cell Ther. 2(7)2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4(e05005)2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Li L, Kang L, Zhao W, Feng Y, Liu W, Wang
T, Mai H, Huang J, Chen S, Liang Y, et al: miR-30a-5p suppresses
breast tumor growth and metastasis through inhibition of
LDHA-mediated Warburg effect. Cancer Lett. 400:89–98.
2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zhu B, Cao X, Zhang W, Pan G, Yi Q, Zhong
W and Yan D: MicroRNA-31-5p enhances the Warburg effect via
targeting FIH. FASEB J. 33:545–556. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Qased AB, Yi H, Liang N, Ma S, Qiao S and
Liu X: MicroRNA-18a upregulates autophagy and ataxia telangiectasia
mutated gene expression in HCT116 colon cancer cells. Mol Med Rep.
7:559–564. 2012.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Faubert B, Boily G, Izreig S, Griss T,
Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, et
al: AMPK is a negative regulator of the warburg effect and
suppresses tumor growth in vivo. Cell Metab. 17:113–124.
2013.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Xian S, Shang D, Kong G and Tian Y: FOXJ1
promotes bladder cancer cell growth and regulates Warburg effect.
Biochem Biophys Res Commun. 495:988–994. 2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Raz S, Sheban D, Gonen N, Stark M, Berman
B and Assaraf YG: Severe hypoxia induces complete antifolate
resistance in carcinoma cells due to cell cycle arrest. Cell Death
Dis. 5(e1067)2014.PubMed/NCBI View Article : Google Scholar
|
